BenevolentAI: The British AI Pioneer Transforming Drug Discovery and Life Sciences

BenevolentAI is a British artificial intelligence and TechBio company with a strong focus on medicine and life sciences. It was founded in 2013 with the aim of helping scientists understand vast amounts of biomedical knowledge. The company combines artificial intelligence, machine learning and scientific expertise to support drug discovery. Its work has attracted attention from global pharmaceutical groups and medical researchers.

BenevolentAI and Its Core Mission

The company was created to solve a major problem in modern science. Every year, huge volumes of medical and biological research are produced across the world. No single scientist or research team can study every paper, dataset and biological connection. BenevolentAI develops systems that help experts process this knowledge and make stronger scientific decisions.

Its approach does not seek to replace doctors, researchers or scientists. Instead, artificial intelligence is used as a tool that extends human ability. The technology can connect diseases, genes, proteins, compounds and biological processes within one digital system. Scientists can then study those relationships when developing new ideas for treatments.

The Founding of BenevolentAI

The business was founded in 2013 and is strongly associated with British entrepreneur Kenneth “Ken” Mulvany. Michael Brennan and Dr Ivan Griffin have also been recognised as co-founders of the company. BenevolentAI Bio Limited was first incorporated under the name Stratified Medical Limited in November 2013. BenevolentAI Limited was later incorporated in the United Kingdom in September 2015.

Kenneth Mulvany and His Role

Ken Mulvany had experience in biotechnology before starting the company. He founded Proximagen, a biotechnology business focused on treatments for neurological and psychiatric diseases. After Proximagen was sold, Mulvany moved towards the use of advanced technology in medical research. His vision helped shape BenevolentAI into an early leader in AI-powered drug discovery.

Mulvany served as chairman during the company’s early years before leaving that position in 2021. He returned to the board in 2024 as the business entered another major stage of change. In October 2024, he became Executive Chairman after Dr Joerg Moeller stepped down from the chief executive role. He also became a director of the main UK company in March 2026.

BenevolentAI Quick Info

How BenevolentAI Uses Artificial Intelligence

BenevolentAI has built technology that can analyse complex scientific and medical material. Its systems combine machine learning, natural-language processing, biomedical data and advanced scientific models. These tools can identify connections that may be difficult for humans to detect through traditional research methods. The aim is to help researchers choose stronger targets and make better drug-development decisions.

The BenevolentAI Knowledge Graph

One of the company’s most important technologies is its biomedical Knowledge Graph. It connects large amounts of scientific material in a structured digital network. Genes, proteins, diseases, drugs and biological processes can be linked based on scientific evidence. Researchers can then explore these connections and create new hypotheses for further laboratory testing.

The Knowledge Graph is supported by proprietary ontologies that organise scientific concepts into meaningful groups. This structure helps the AI understand how different biomedical ideas relate to one another. It also allows scientists to study complex disease mechanisms more efficiently. Human judgement remains important when deciding whether an AI-generated idea has medical value.

BenevolentAI and the Baricitinib Discovery

The company gained global attention during the COVID-19 pandemic because of its work involving baricitinib. Baricitinib was already an approved medicine before the pandemic began. The company’s AI identified it as a possible treatment for patients affected by COVID-19. Scientists believed the medicine could influence both inflammation and biological processes linked with viral infection.

Further clinical research later supported the use of baricitinib for certain hospitalised COVID-19 patients. The case became one of the best-known examples of artificial intelligence assisting drug repurposing. It showed how existing medicines could be examined for new medical uses at greater speed. The achievement also increased global interest in AI-based biomedical research.

BenevolentAI and AstraZeneca

A major partnership with AstraZeneca began in 2019. The first programmes focused on chronic kidney disease and idiopathic pulmonary fibrosis. The collaboration combines AstraZeneca’s scientific knowledge with AI-based target identification and biomedical data analysis. It later expanded into heart failure and systemic lupus erythematosus.

By 2024, multiple targets created through this collaboration had entered AstraZeneca’s research portfolio. The partnership also generated significant commercial income for the AI company. By September 2024, the relationship had produced about £32 million since its launch. Further milestone payments and royalties may become available if future development goals are achieved.

BenevolentAI and Merck KGaA

The company formed another major strategic collaboration with Merck KGaA in 2023. The agreement covers research within oncology, neurology and immunology. Its AI platform helps identify possible drug candidates before they move into deeper laboratory development. Merck contributes pharmaceutical expertise and experience in turning scientific discoveries into potential medicines.

The agreement has a possible total value of up to US$594 million if agreed milestones are achieved. This includes early payments as well as possible discovery, development and commercial payments. Royalties may also become payable if medicines created through the programme reach the market. The partnership gives the company another route for earning income from its technology.

BenevolentAI Drug Development Programmes

The company has also developed its own experimental drug candidates. BEN-8744 became one of its most advanced programmes and was developed for moderate to severe ulcerative colitis. It is an oral PDE10 inhibitor designed to act mainly outside the central nervous system. A Phase Ia study completed in 2024 produced positive safety and pharmacokinetic results.

BEN-34712 and BEN-28010

BEN-34712 was developed as a possible treatment for amyotrophic lateral sclerosis, also known as ALS. It is designed to enter the brain and affect specific retinoic acid receptors. BEN-28010 was developed for glioblastoma and metastatic brain tumours. Both programmes formed part of the company’s effort to turn AI-generated discoveries into real drug candidates.

The BEN-2293 Setback

Not every programme achieved the desired results. BEN-2293 was tested as a treatment for mild to moderate atopic dermatitis. Its Phase IIa study met the main safety goal but failed to achieve key efficacy goals for inflammation and itching. The company therefore decided to stop further investment in the programme.

This result showed an important truth about artificial intelligence in medicine. AI can help identify targets and improve scientific decision-making, but it cannot remove the risks of clinical development. Drug trials still depend on biology, safety and patient response. Success requires strong technology combined with careful laboratory and clinical work.

BenevolentAI and the Qor Platform

Qor is an important part of the company’s newer business direction. It is a strategic decision-intelligence platform designed for biotechnology leaders and life-science advisers. The system helps teams study scientific assets, competitors, markets and possible business opportunities. It aims to turn complex evidence into clear and useful strategic briefings.

Qor also expands the company beyond traditional drug discovery. Biotechnology executives can use the platform when studying partnerships, investments, development choices and competitive threats. This creates another possible source of revenue for the business. It also allows years of AI and biomedical knowledge to support commercial decisions across the life-science sector.

Financial Growth and Major Restructuring

The company attracted large amounts of investment during its expansion. In 2018, it secured approximately US$115 million at a valuation of about US$2.1 billion. It later entered the Euronext Amsterdam market in April 2022 through a combination with Odyssey Acquisition. The transaction generated about €225 million in gross proceeds.

However, high research costs and clinical setbacks placed pressure on the business. Revenue was £10.6 million in 2022 and £7.3 million in 2023. During the first half of 2024, revenue reached about £2.8 million while the operating loss was more than £32 million. These pressures led management to reduce spending and change strategic priorities.

Workforce Changes at BenevolentAI

Major restructuring began during 2023 after disappointing results from BEN-2293. The company announced plans to remove up to 180 positions and reduce annual costs substantially. It had 248 full-time-equivalent employees at the end of 2023. Another restructuring programme followed during 2024 as management worked to protect cash resources.

The company also closed its United States office and placed greater focus on operations in Britain. London and Cambridge became the main centres of activity. Further workforce changes followed as the business returned to its original TechBio strengths. Current social-media employee categories may therefore be higher than the company’s actual workforce.

BenevolentAI Returns to Private Ownership

A major corporate change took place in March 2025. Shareholders approved a merger between the company and Osaka Holdings S.à r.l. The combined business then adopted the BenevolentAI name. Trading of the former shares on Euronext Amsterdam ended on 13 March 2025.

Returning to private ownership reduced many costs connected with operating on a major stock exchange. Management wanted more resources directed towards technology, science and commercial development. The private structure also gave the company greater freedom to reshape its strategy. The former BAI stock ticker should therefore not be treated as a current trading symbol.

BenevolentAI Headquarters and Corporate Structure

The main UK headquarters is at 4–8 Maple Street, London W1T 5HD. The wider parent structure also has a registered presence in Luxembourg. Important British entities include BenevolentAI Limited, BenevolentAI Bio Limited and BenevolentAI Technology Limited. The company has also maintained scientific activity connected with Cambridge.

Leadership Changes in 2026

Further corporate changes took place during March 2026. Ken Mulvany became a director of BenevolentAI Limited on 10 March. James Hunter became a director later that month. Michael Brennan and Ivan Griffin ended their UK directorships during the same period.

Why BenevolentAI Matters in Modern Medicine

BenevolentAI has become an important example of how artificial intelligence can support medical research. Its work with baricitinib showed that AI can help scientists examine existing drugs for new uses. Partnerships with AstraZeneca and Merck show that large pharmaceutical companies see value in this technology. Its own drug programmes also demonstrate the difficulty of turning computer-generated ideas into successful medicines.

The company has experienced rapid growth, scientific achievements, financial pressure and major restructuring. These experiences provide a balanced view of the AI drug-discovery sector. Artificial intelligence can improve speed and understanding, but strong science remains essential. Clinical success still requires testing, evidence and careful medical judgement.

The Future of BenevolentAI

BenevolentAI now operates as a private TechBio company with more than a decade of experience in biomedical artificial intelligence. Its Knowledge Graph, pharmaceutical collaborations and drug-discovery expertise remain important parts of the business. Qor adds a new strategic intelligence direction that may widen its commercial reach. The next stage will depend on turning scientific technology into sustainable products, partnerships and medical value.

Also Read

• MCN Media: Transforming Faith, Streaming and Community Connection Across Europe
• Humanloop: The AI Platform That Transformed LLM Development Before Joining Anthropic
• Hawk-Eye Innovations: Transforming the Future of Sports Technology